|
Model Number 105-5082-145 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Stenosis (2263); Thromboembolism (2654)
|
Event Date 11/22/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
Event related to regulatory reports: 2029214-2022-02005, 2029214-2022-02006, 2029214-2022-02007 medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Medtronic received information that a solitaire fr stent had resistance in a rebar 18 catheter and broke.When another solitaire was used there were complications.Guided by the micro-guide wire with a micro-catheter (rebar 18), using coaxial technology, guided the intermediate catheter to the lower end of the basilar artery, passed the micro-guide wire and micro-catheter through the occlusion segment, withdrew the micro-guide wire.Microcatheter microangiography showed that the distal vascular bed was well developed, intermediate catheter angiography showed that the thrombus load capacity.Then the solitaire fr 6mm"30mm stent was slowly pushed through the microcatheter.During the pushing process, the stent was difficult to push, and the push was dry.After pushing the stent into the microcatheter for 15cm, it was still difficult to push the stent, and then retracted the stent.During the retraction process, the stent broke.The distal end of the stent remained in the microcatheter, and the microcatheter was withdrawn (rebar 18).Under the guidance of the micro-guide wire with microcatheter (rebar 27), passed the micro-guide wire and the micro-catheter through the occluded segment of the basilar artery, withdrew the micro-guide wire.The solitaire fr6mm*30mm stent was replaced, and then the solitaire fr 6mm*30mm stent was slowly pushed and deployed through the microcatheter to cover the thrombus.The microcatheter was withdrawn, and the angiography showed that the blood vessel was partially recanalized.After the stent self-expanded for 5 minutes, the stent was recovered and continuously sucked through the intermediate catheter, and a large number of thrombus was seen.The dark red thrombus attached to the stent was seen; the guide catheter angiography showed recanalization of the basilar artery, the distal blood flow mtic1 was grade 2b, the lower end of the basilar artery was severely narrowed, and the blood flow was difficult to maintain.Delivered the micro guide wire to the left posterior cerebral artery, delivered the intracranial balloon (2.75*20) to the stenosis al ong the micro guide wire, after the alignment was accurate, filled the balloon with 6atm pressure, withdrew the balloon, and delivered the system , re-examination angiography, stenosis improved than before.The stent was delivered to the stenosis along the micro-g uide wire, deployed after the alignment was accurate, the stent delivery system was withdrawn, reexamined the angiography, and the stenosis was significantly improved, and the stenosis rate was less than 20%.The forward blood flow improved, the intermediate catheter was withdrawn, and the guiding catheter angiography showed bilateral posterior cerebral arteries and bilateral superior cerebellar arteries in the brain, which were well developed.Withdrew the guiding catheter and ended the operation.The resistance was in the distal section of the catheter.It broke at the detachment point.The devices were prepared as indicated in the instructions for use (ifu).The patient was being treated for an ischemic stroke in the basilar artery.Mrs: baseline 0.Mrs: procedure 4.Nihss score: baseline 30.Nihss score: post procedure 30.Tici score: baseline 0.Tici score: post procedure (level 3).Iv tpa was not contraindicated.One pass was made with the device.Vessel tortuosity was severe.Ancillary devices: 5f navien 125 distal access catheter, avigo guidewire, intracranial dilatation balloon.
|
|
Event Description
|
New information was received.The patient's weight at the time of the reported event was 65 kg.The patient improved slightly after the surgery, and could move the lower limbs according to the instructions, and the muscle strength of the upper limbs was paralyzed at level 2.The patient experienced related symptoms, this time was acute onset related to the stenosis.The relationship between stenosis and thrombus couldn't be determined.It was considered as post-stenosis thrombosis.Solitare lot #'s: lot number that had resistance and broke: b315735, second fr lot number: b316305.The rebar lot#'s: rebar18 lot number:b230926;rebar27 lot number:b344536.
|
|
Manufacturer Narrative
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|